# Understanding Mammalian Metabolic Flux into N-glycans by Stable Isotopic Tracing Analysis Idris Wazeerud-Din<sup>1</sup>, Robin Kemperman<sup>1</sup>, Andrew Edmondsmon<sup>1,2</sup>, Ralph DeBardinis<sup>3</sup>, Stephen Master<sup>1,2</sup>, and Miao He<sup>1</sup>

(1) Children's Hospital of Philadelphia, (2) University of Pennsylvania Perelman School of Medicine, (3) UT Southwestern Medical Center

## Abstract

Congenital disorders of glycosylation (CDG) are one of the largest groups of inborn errors of metabolism with more than 170 types identified, most of which are under-studied. Among all the CDGs, PMM2-CDG is the most common and affects more than 50% of the CDG patients in the country. Recently, significant progress has been made in developing novel therapies for PMM2-CDG, including aldolase reductase inhibitors and mannose-1-phosphate based therapies. By increasing monosaccharide flux into N-linked glycoprotein biosynthesis, significant clinical improvement and developmental gains have been achieved in affected children on these therapies. This study aims to monitor the metabolic flux of uniformly labeled  ${}^{15}N_2$ -glutamine and  ${}^{13}C_6$ -glucose in human fibroblast cells and the whole-body tracing in mice of incorporated isotopically labeled N-glycans using in-depth highresolution mass spectrometry (HRMS) methods.

# Results

8×10<sup>5</sup>-

6×10<sup>5</sup>-

4×10<sup>5</sup>

\_ ₅10×2 <u>کانک</u>

อั 8×10⁴ т

4×10<sup>4</sup>-

2×10<sup>4</sup>

⊑ 6×10⁴-



#### Quantification of heavy isotope <sup>15</sup>N-Glycan in IgG



Percentage of Uniformly Labeled IgG



PMM2-CDG (CDG-1a) Patients: Childhood to Aldulthood. Chang, I., et. Al.

#### Introduction



(Right) Overlay MS<sup>1</sup> spectra of Rapi-fluor tag Fucosylated-A-Gal N-Glycan mixture with labeled IgG and <sup>15</sup>N-Labelled IgG to determine limit of detection of isotopically labeled N-glycan at a range of 0.01% to 50%. We determined that 0.1% mixture was the detection limit. (Left) Zoomed m+0 and m+4 isotopic peaks used for quantifying mixture.

- · Control Mouse Liver

- • Infused Mouse Liver

**Fucosylated Agal** 

Synapt Spectra

Standard curve of labelled Fucosylated-Agal by serially diluting 10ug/mL <sup>15</sup>N-lgG Nglycan in 10 ug/mL lgG analyzed by Synapt G2-Si. The resolution and sensitivity allowed for large linear range that's use to estimate the amount of heavy labelled N-IgG N-Glycan. The linearity was shown to be 0.001ug/mL-10ug/mL (0.9994r<sup>2</sup>) for<sup>15</sup>N-Fucosylated A-Gal Glycan from IgG.

 $MS^2$ 

---**>** 

Fucosylated Agal (GlcNAc+GlcNAc) (m-

Children's Hospital of Philadelphia<sup>®</sup>

#### <sup>15</sup>N-Glutamine whole-body tracing in mouse tissue

Synapt G2-Si MS<sup>1</sup> spectra overlay of infused mouse liver and wild-type mouse liver. Shows increase in the m+4 peak, which calculates to an 5% increase of <sup>15</sup>N-30% Difference uniformally labelled Fucosylated A-Gal N-Glycan from a 4hr infusion <sup>15</sup>N-Glutamine intravenously.

### <sup>15</sup>N-Glutamine tracing in human fibroblast





Orbitrap MS<sup>1</sup> spectra overlay of infused mouse liver and IgG mixture solutions. The infused mouse liver shows a shoulder at the m+4 peak, which indicates a small percentage of fully labelled <sup>15</sup>N- $(GlcNAc)_4$ -Fucosylated A-Gal but rather a higher percentage of <sup>15</sup>N-(GlcNAc)<sub>1</sub>-Fucosylated A-Gal. MS<sup>2</sup> spectra overlay shows <sup>15</sup>N incorporation in into the GlcNAc's fragments, but very small incorporation into GlcNAc + GlcNAc fragment.





<sup>15</sup>N-Glutamine flux for 24,48, and 72 hrs. into N-Glycan demonstrates impaired functionality in PMM2-CDG cell lines in comparison to normal fibroblast cells. Metabolic flux is increasingly distinguishable in complex and high mannose glycans in comparison to low mannose species.

# Methodology



<sup>13</sup>C-Glucose flux for 12, 24, 48 and 72 hrs. into N-Glycan demonstrates similar impaired metabolic flux in PMM2-CDG cell lines of <sup>15</sup>N-Glutamine. The data shows a profound difference with complex glycans and high mannose versus low mannose. The flux linearity differs from glutamine because the complex glucose metabolism, which affects a variety of monosaccharides at different stages of mammalian metabolic pathway into N-Glycans.

Discussion



(1a) <sup>15</sup>N<sub>2</sub>-Glutamine Infusion. (1b) Human Fibroblast treated media. (2) Tissue

Extraction. (3) Homogenizatinon & Cell Disruption. (4) PNGase. (5)

Derivatization (6) Hilic Cleanup. (7) MS. (8) Data Analysis.

Our method provides an important paradigm to study mammalian metabolic flux into Nlinked protein glycosylation both in vitro and in vivo.

Future direction would be to further characterize metabolic flux into each monosaccharide

using MS<sup>n</sup> technology., also quantify metabolic flux in both additional mouse organ and in other CDG human fibroblast cell lines.

